Protalix BioTherapeutics Inc. earnings at a glance (GAAP) : -Earnings: $2.93 Mln. vs. $8.31 Mln. last year. -EPS: $0.04 vs. $0.09 last year. -Revenue: $53.40 Mln vs. $65.49 Mln last year.

SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor ...

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value ...

Steminent Biotherapeutics develops stem cell therapies for neurodegenerative and other diseases. The Taiwanese biotech company’s approach involves the use of mesenchymal stem cells (MSCs). Its lead ...

Iovance Biotherapeutics recently reaffirmed its earnings guidance for 2025 and projected significant revenue growth for 2026, alongside announcing a notable revenue increase in its 2024 earnings ...

Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate. Atara ...

Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price objective trimmed by Truist Financial from $25.00 to $15.00 in a research note issued to investors on Monday morning,Benzinga ...

Chardan lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $30 from $34 and keeps a Buy rating on the shares. The company reported Q4 results, provided an update on the Amtagvi ...